摘要
为了比较培美曲塞联合顺铂与多西他赛联合顺铂二线治疗晚期肺腺癌的临床疗效,将符合入组标准的68例晚期肺腺癌患者随机分为观察组与对照组,每组34例。观察组以培美曲塞联合顺铂化疗,对照组多西他赛联合顺铂化疗。治疗后,CR两组均为0,两组相比差异无统计学意义,P>0.05。疾病控制率(DCR),观察组为23.53%,对照组为20.59%,两组相比差异无统计学意义,P>0.05。毒副反应Ⅱ～Ⅳ级发生率观察组低于对照组,差异有统计学意义,P<0.05。培美曲塞联合顺铂二线治疗肺腺癌临床疗效与多西他赛联合顺铂二线治疗晚期肺腺癌的临床疗效相当,但毒副反应发生率降低。
The objective of this study was to compare pemetrexed combined cisplatin with docetaxel combined cisplatin in second-line therapy for advanced lung adenocarcinoma patients.A total of 68 cases of advanced lung adenocarcinoma patients were randomly divided into observation group and control group,and 34 cases in each group.The patients in observation group were treated with pemetrexed combined cisplatin,and the patients in control group were treated with docetaxel combined cisplatin.After treatment,CR of both groups were 0,and there was no significant difference （P〉0.05）.Disease control rates （DCR） were 23.53% in observation group and 20.59% in control group,and there was no significant difference （P〉0.05）.TheⅡ-Ⅳ side effect incidence rate in observation group was significantly lower than that in control group （P〈0.05）.In conclusion,pemetrexed combined cisplatin and docetaxel combined cisplatin for the treatment of lung adenocarcinoma patients have similar treatment outcome,and the side effect of pemetrexed combined cisplatin is lower.
出处
《中华肿瘤防治杂志》
CAS
2010年第14期1127-1128,共2页
Chinese Journal of Cancer Prevention and Treatment
